Search

Displaying results 8201 - 8210 of 9710 in total
  1. Drug

    INCB13739

    go.drugbank.com/drugs/DB05064
    Investigational

    INCB13739 is developed as a new treatment for type 2 diabetes.

  2. Drug

    AV608

    go.drugbank.com/drugs/DB05072
    Investigational

    AV608 is a NK-1 antagonist. It is developed for the treatment of Social anxiety disorder (SAD), irritable bowel syndrome (IBS) and overactive bladder (OAB).

  3. Drug

    SLV319

    go.drugbank.com/drugs/DB05077
    Experimental

    SLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid type 1 (CB1) receptor.

  4. Drug

    HY10275

    go.drugbank.com/drugs/DB05079
    Experimental

    HY10275 is a novel compound specifically designed to modulate two key neurobiological mechanisms that interfere with the sleeping process.

  5. Drug

    OBE101

    go.drugbank.com/drugs/DB05080
    Experimental

    OBE101 is a new weight loss drug developed by Obecure Ltd. It is a new formulation that is based on the vertigo medication, Betahistine.

  6. Drug

    FP0011

    go.drugbank.com/drugs/DB05090
    Experimental

    FP0011 is a small molecule antiglutamatergic compound with symptomatic and disease modifying effects in a variety of neurological disorders (amyotrophic lateral sclerosis and Parkinson's disease).

  7. Drug

    Matuzumab

    go.drugbank.com/drugs/DB05101
    Investigational

    Matuzumab (formerly known as the experimental drug, EMD 72000) is a humanized monoclonal antibody used in cancer treatment. … It has a high affinity for EGFR (epithelial growth factor receptor), frequently associated with the growth of blood vessels in malignancy, facilitating tumor growth and survival.

  8. Drug

    Pleconaril

    go.drugbank.com/drugs/DB05105
    Investigational

    Pleconaril is an antiviral drug from viral capsid inhibitor class, manufactured by Schering-Plough and intended for the prevention of acute asthma exacerbations and common cold symptoms in asthmatic patients who have had exposure to pico...

  9. Drug

    EHT899

    go.drugbank.com/drugs/DB05108
    Experimental

    EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection. … It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load.

  10. Drug

    AP5280

    go.drugbank.com/drugs/DB05112
    Experimental

    AP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.